North America
South America
Australia & New Zealand
Europe
Middle East / Africa
Asia / Pacific
×
×
FITC Mouse Anti-Human HLA-DR L243 体外診断用医薬品

FITC Mouse Anti-Human HLA-DR 

Clone  L243   (体外診断用医薬品)

  • Concentration 25 μg/mL
  • Vol. Per Test 20 μL
  • Isotype Mouse IgG2a, κ
  • Reactivity Human (QC Testing) 
  • Application Flow cytometry (Routinely Tested) 
  • Immunogen Human lymphoblastoid B-cell line RPMI 8866
  • Entrez Gene ID 0 
  • Storage Buffer Phosphate buffered saline with gelatin and 0.1% sodium azide.
  • Regulatory Status 体外診断用医薬品
Product Details Recommended Assay References

Description

Anti–HLA-DR, clone L243, is derived from the hybridization of mouse NS-1/1-Ag4 myeloma cells with spleen cells from BALB/c mice immunized with the human lymphoblastoid B-cell line RPMI 8866.

Anti–HLA-DR recognizes a human class II major histocompatibility complex (MHC) antigen. The antigen is a transmembrane glycoprotein composed of α- and β-subunits that have molecular weights of 36 and 27 kilodaltons (kd), respectively.

Format
  • Format FITC
  • Excitation Source Blue 488 nm
  • Excitation Max 494 nm
  • Emission Max 520 nm

FITC, fluorescein isothiocyanate, is a fluorochrome with a molecular weight of 389 Da. FITC is sensitive to pH changes and photobleaching. Due to nearly identical excitation and emission properties but different spillover characteristics, FITC and Alexa Fluor® 488 cannot be used simultaneously. FITC is relatively dim and should be reserved for highly expressed markers whenever possible.

Other Formats →

Resources & Tools
 Spectrum Viewer  Panel Designer  Spectrum Viewer  Download TDS  Package Insert  Regulatory Document Website
Preparation and Storage

Store vials at 2° to 8°C. Conjugated forms should not be frozen and should be protected from exposure to light. Each reagent is stable for the period shown on the bottle label when stored as directed.


  1. Brodsky FM. A matrix approach to human class II histocompatibility antigens: reactions of four monoclonal antibodies with the products of nine haplotypes. Immunogenetics. 1984;19:179-194.

  2. Edwards JA, Durant BM, Jones DB, Evans PR, Smith JL. Differential expression of HLA class II antigens in fetal human spleen: relationship of HLA-DP, DQ, and DR to immunoglobulin expression. J Immunol. 1986;137:490-497.

  3. Engleman EG, Warnke R, Fox RI, Dilley J, Benike CJ, Levy R. Studies of a human T lymphocyte antigen recognized by a monoclonal antibody. Proc Natl Acad Sci USA. 1981;78:1791-1795.

  4. Grouard G, Durand I, Filgueira L, Banchereau J, Liu YL. Dendritic cells capable of stimulating T cells in germinal centres. Nature. 1996;384:364-367.

  5. Lampson LA, Levy R. Two populations of Ia-like molecules on a human B cell line. J Immunol. 1980;125:293-299.

  6. Levacher M, Tallet S, Dazza M, Dournon E, Rouveix B, Pocidalo J. T activation marker evaluation in ARC patients treated with AZT: comparison with CD4+ lymphocyte count in non-progressors and progressors towards AIDS. Clin Exp Immunol. 1990;81:177-182.

  7. O'Doherty U, Peng M, Gezelter S, et al. Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature. Immunology. 1994;82:487-493.

  8. Robbins PA, Evans EL, Ding AH, Warner NL, Brodsky FM. Monoclonal antibodies that distinguish between class II antigens (HLA-DP, DQ, and DR) in 14 haplotypes. Human Immunol. 1987;18:301-313.

  9. Stites DP, Casavant CH, McHugh TM, et al. Flow cytometric analysis of lymphocyte phenotypes in AIDS using monoclonal antibodies and simultaneous dual immunofluorescence. Clin Immunol Immunopathol. 1986;38:161-177.

  10. Terstappen LWMM, Hollander Z, Meiners H, Loken MR. Quantitative comparison of myeloid antigens on five lineages of mature peripheral blood cells. J Leuk Biol. 1990;48:138-148.

  11. Thomas R, Lipsky PE. Human peripheral blood dendritic cell subsets: isolation and characterization of precursor and mature antigen-presenting cells. J Immunol. 1994;153:4016-4027.

  12. Tomkinson B, Wagner D, Nelson D, Sullivan J. Activated lymphocytes during acute Epstein-Barr virus infection. J Immunol. 1987;139:3802-3807.

  13. van Es A, Baldwin WM, Oljans PJ, Tanke HJ, Ploem JS, van Es LA. Expression of HLA-DR on T lymphocytes following renal transplantation, and association with graft-rejection episodes and cytomegalovirus infection. Transplantation. 1984;37:65-69.

  14. Warnke R, Miller R, Grogan T, Pederson M, Dilley J, Levy R. Immunologic phenotype in 30 patients with diffuse large-cell lymphoma. N Eng J Med. 1980;303:293-300.

  15. Warnke RA, Levy R. Detection of T and B cell antigens with hybridoma monoclonal antibodies: a biotin-avidin-horseradish peroxidase method. J Histochem Cytochem. 1980;303:293-300.

  16. Zipf RF, Fox R, Dilley J, Levy R. Definition of the high risk ALL patient by immunologic phenotyping with monoclonal antibodies. Cancer Res. 1981;41:4786.

347363 Rev.
Instruments
Reagents
Applications
Sales & Support
BD BioSciences